Journal of Peking University(Health Sciences) >
Correlation of anti-phosphatidylserine/prothrombin antibodies with unexplained recurrent miscarriages
Received date: 2023-08-13
Online published: 2023-12-11
Supported by
the Joint Project of the Peking University Third Hospital and the Enterprise(CON20210900013)
Objective: To investigate whether anti-phosphatidylserine/prothrombin antibodies and its IgG or IgM subtypes were correlated with unexplained recurrent miscarriages. Methods: In our a single-center retrospective study, 283 patients with at least one unexplained miscarriage who visited the Third Hospital of Peking University between January 2021 and August 2023, aged between 18-40 years, and tested for anti-phosphatidylserine/prothrombin antibodies IgG or IgM subtypes, were included. The patients with either positive IgG or IgM anti-phosphatidylserine/prothrombin antibody were regarded as positive for anti-phosphatidylserine/prothrombin antibody. SPSS 26.0 software was used for statistical analysis. Chi-square test and Logistic regression analysis were used to study the correlation of anti-phosphatidylserine/prothrombin antibodies and its IgG or IgM subtypes with unexplained recurrent miscarriages. And the diagnostic sensitivity, specificity, the positive predictive value, the negative predictive value of anti-phosphatidylserine/prothrombin antibodies and its IgG or IgM subtypes in unexplained miscarriages was calculated with four-fold table. Results: Chi-square analysis showed that anti-phosphatidylserine/prothrombin antibodies and its IgM subtypes were correlated with recurrent miscarriages (both P < 0.05), while the IgG subtype was not correlated with recurrent miscarriages (P>0.05). After adjusting with anticardiolipin antibodies, anti-β2 glycoprotein antibodies, lupus anticoagulants, antinuclear antibodies, and age by Logistic regression analysis, anti-phosphatidylserine/prothrombin antibodies were correlated with unexplained recurrent miscarriages (OR=2.084, 95%CI 1.045-4.155, P < 0.05), and anti-phosphatidylserine/prothrombin antibody IgM subtypes were correlated with unexplained recurrent miscarriages (OR=2.368, 95%CI 1.187-4.722, P < 0.05).The sensitivity of anti-phosphatidylserine/prothrombin antibody in recurrent miscarriage was 65.43%, the specificity was 48.51%, the positive predictive value was 33.76%, and the negative predictive value was 77.78%. In the patients with recurrent miscarriages with negative classical antiphospholipid antibodies, the sensitivity of anti-phosphatidylserine/prothrombin antibody was 59.09%, the specificity was 63.23%, the positive predictive value was 40.63%, and the negative predictive value was 78.40%. The sensitivity of the anti-phosphatidylserine/prothrombin antibody IgM subtype for the diagnosis of recurrent miscarriage was 65.43%, the specificity was 50.99%, the positive predictive value was 34.87%, and the negative predictive value was 78.63%. Conclusion: Anti-phosphatidylserine/prothrombin antibody and IgM subtype antibody are correlated with unexplained recurrent miscarriages in patients with at least one unexplained miscarriage. Whether positive anti-phosphatidylserine/prothrombin antibody or IgM subtype could predict future unexplained recurrent miscarriages warrants a prospective study.
Zhong-qiang YAO , Chang-hong LI , Xin-yi LI , Wei GUO , Jia-yu ZHAI , Rui LIU , Hui WEI , Rong MU . Correlation of anti-phosphatidylserine/prothrombin antibodies with unexplained recurrent miscarriages[J]. Journal of Peking University(Health Sciences), 2023 , 55(6) : 1058 -1061 . DOI: 10.19723/j.issn.1671-167X.2023.06.016
| 1 | Coomarasamy A , Dhillon-Smith RK , Papadopoulou A , et al. Recurrent miscarriage: Evidence to accelerate action[J]. Lancet, 2023, 397 (10285): 1675- 1682. |
| 2 | Regan L , Rai R , Saravelos S , et al. Recurrent miscarriage green-top guideline No.17[J]. BJOG, 2023, 130 (12): e9- e39. |
| 3 | Alijotas-Reig J , Ferrer-Oliveras R , Rodrigo-Anoro MJ , et al. Anti-beta(2)-glycoprotein-Ⅰ and anti-phosphatidylserine anti-bodies in women with spontaneous pregnancy loss[J]. Fertil Steril, 2010, 93 (7): 2330- 2336. |
| 4 | Vlagea A , Gil A , Cuesta MV , et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome[J]. Clin Appl Thromb Hemost, 2013, 19 (3): 289- 296. |
| 5 | Zhang S , Wu Z , Zhang W , et al. Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome[J]. Clin Chem Lab Med, 2018, 56 (6): 939- 946. |
| 6 | Zhang X , Liu Z , Guo F , et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) and risk of obstetric anti-phospholipid syndrome[J]. Am J Reprod Immunol, 2023, 89 (6): e13621. |
| 7 | Shi H , Zheng H , Yin Y , et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome[J]. Clin Chem Lab Med, 2018, 56 (4): 614- 624. |
| 8 | 张建平, 王谢桐, 徐国才, 等. 复发性流产诊治专家共识(2022)[J]. 中华妇产科杂志, 2022, 57 (9): 653- 667. |
| 9 | Hennessy M , Dennehy R , Meaney S , et al. Clinical practice guidelines for recurrent miscarriage in high-income countries: A systematic review[J]. Reprod Biomed Online, 2021, 42 (6): 1146- 1171. |
| 10 | Barbhaiya M , Zuily S , Naden R , et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria[J]. Ann Rheum Dis, 2023, 82 (10): 1258- 1270. |
| 11 | Vogt E , Ng AK , Rote NS . A model for the antiphospholipid antibody syndrome: Monoclonal antiphosphatidylserine antibody induces intrauterine growth restriction in mice[J]. Am J Obstet Gynecol, 1996, 174 (2): 700- 707. |
| 12 | Matalon ST , Shoenfeld Y , Blank M , et al. Antiphosphatidylserine antibodies affect rat yolk sacs in culture: A mechanism for fetal loss in antiphospholipid syndrome[J]. Am J Reprod Immunol, 2004, 51 (2): 144- 151. |
/
| 〈 |
|
〉 |